Cardiovascular Drugs Practice Questions

Q: Supraventricular tachycardia can be managed best by:

Adenosine. **Explanation:** **Adenosine** is the drug of choice for the acute termination of Paroxysmal Supraventricular Tachycardia (PSVT), including those involving accessory pathways (WPW syndrome). It works by activating A1 receptors in the AV node, leading to increased potassium efflux and inhibition of calcium current. This results in profound hyperpolarization and a transient "chemical cardioversion" by blocking AV nodal conduction. Its ultra-short half-life (<10 seconds) makes it ideal for emergency use with minimal prolonged side effects. **Analysis of Incorrect Options:** * **Digitalis (Digoxin):** While it can be used for rate control in atrial fibrillation by increasing vagal tone, its onset of action is too slow (hours) for the acute management of SVT. * **Disopyramide & Quinidine:** These are Class IA antiarrhythmics. They are rarely used for SVT today due to their potential for pro-arrhythmia and significant side effects (e.g., anticholinergic effects of disopyramide, cinchonism with quinidine). Furthermore, they can paradoxically increase ventricular rate in atrial flutter/fibrillation by improving AV conduction. **High-Yield Clinical Pearls for NEET-PG:** * **Administration:** Adenosine must be given as a **rapid IV bolus** (usually 6mg, followed by 12mg) through a large-bore peripheral vein, followed by a saline flush, due to its rapid metabolism by erythrocytes and endothelial cells. * **Contraindications:** Avoid in **Asthmatics** (can cause bronchospasm via A2B receptors) and patients with **high-grade heart block**. * **Interactions:** Its effects are antagonized by **Theophylline/Caffeine** (adenosine receptor antagonists) and potentiated by **Dipyridamole**. * **Side Effects:** Patients often experience a transient, distressing sense of "impending doom," chest pain, or flushing.

Q: Which of the following drugs has been used in the treatment of angina by the inhalation route with a very rapid onset and short duration of action?

Amyl nitrite. **Explanation:** **Amyl nitrite** is the correct answer because it is a highly volatile liquid administered via **inhalation**. It is supplied in glass ampoules that are crushed and inhaled, leading to a very rapid onset of action (within 30 seconds) but a very short duration of effect (3–5 minutes). While it was historically used for acute angina, its primary clinical relevance today is in the emergency management of **cyanide poisoning** due to its ability to induce methemoglobinemia. **Why the other options are incorrect:** * **Isosorbide dinitrate (ISDN):** Primarily administered sublingually or orally. While sublingual ISDN has a rapid onset (2–5 minutes), it is not administered by inhalation and has a longer duration of action (1–2 hours) compared to Amyl nitrite. * **Isosorbide mononitrate (ISMN):** This is the active metabolite of ISDN. It has high oral bioavailability and a long half-life, making it suitable for the **prophylaxis** of angina, not for acute termination via inhalation. * **Nitroglycerin (Glyceryl Trinitrate):** The drug of choice for acute angina. It is typically administered sublingually (tablet or spray) or intravenously. While a lingual spray exists, it is not an "inhalational" drug that reaches the alveoli like Amyl nitrite. **High-Yield NEET-PG Pearls:** * **Cyanide Poisoning:** Amyl nitrite is used because it converts hemoglobin to **methemoglobin**, which has a high affinity for cyanide, forming non-toxic cyanmethemoglobin. * **Diagnostic Use:** In cardiology, Amyl nitrite inhalation is used to differentiate heart murmurs; it **increases** the intensity of the murmur in Hypertrophic Obstructive Cardiomyopathy (HOCM) and Mitral Regurgitation by decreasing systemic vascular resistance. * **Storage:** Organic nitrates (especially Nitroglycerin) must be stored in dark, tightly sealed glass containers because they are sensitive to light and can adsorb to plastic.

Q: Which antihistamine is associated with an increased risk of cardiac arrhythmias when co-administered with erythromycin or ketoconazole?

Terfenadine. **Explanation:** **Correct Option: D (Terfenadine)** Terfenadine is a second-generation H1-antihistamine that acts as a **pro-drug**. It is normally metabolized by the hepatic cytochrome **CYP3A4** enzyme into its active, non-toxic metabolite, fexofenadine. When co-administered with CYP3A4 inhibitors like **Erythromycin** (macrolide) or **Ketoconazole** (azole antifungal), the metabolism of terfenadine is blocked. This leads to high plasma levels of the parent drug, which blocks the delayed rectifier potassium channels ($I_{Kr}$) in the heart. This action prolongs the QT interval, potentially leading to a life-threatening polymorphic ventricular tachycardia known as **Torsades de Pointes**. Due to this risk, terfenadine was withdrawn from the market and replaced by fexofenadine. **Incorrect Options:** * **A & B (Diphenhydramine & Clemastine):** These are first-generation antihistamines. While they have sedative and anticholinergic side effects, they do not significantly block cardiac potassium channels or interact with CYP3A4 to cause Torsades de Pointes. * **C (Loratadine):** This is a second-generation antihistamine. While it is metabolized by CYP3A4, it does not possess the same potent cardiac potassium channel-blocking activity as terfenadine, making it much safer regarding cardiotoxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Astemizole** is another second-generation antihistamine withdrawn for the same reason (QT prolongation). * **Fexofenadine** is the active metabolite of terfenadine; it is safe because it does not block cardiac $K^+$ channels. * **Mnemonic for QT-prolonging drugs:** "ABCDE" – **A**ntiarrythmics (Class IA, III), **B**iotics (Macrolides, Quinolones), **C**ant Psychotics (Haloperidol), **D**epressants (TCAs), **E**metics (Ondansetron).

Q: Which of the following decreases defibrillation threshold?

Sotalol. ### Explanation **Concept: Defibrillation Threshold (DFT)** The Defibrillation Threshold is the minimum electrical energy required to successfully terminate ventricular fibrillation. Drugs that **increase** DFT make it harder to defibrillate a patient, while drugs that **decrease** DFT make the heart more sensitive to electrical cardioversion. **Why Sotalol is Correct:** Sotalol is a Class III antiarrhythmic agent with potent potassium channel-blocking properties. By blocking the delayed rectifier potassium current ($I_{Kr}$), it prolongs the action potential duration (APD) and the effective refractory period (ERP). This increase in cardiac refractoriness lowers the energy required to terminate re-entrant circuits, thereby **decreasing the defibrillation threshold**. This property makes it particularly useful in patients with Implantable Cardioverter Defibrillators (ICDs). **Analysis of Incorrect Options:** * **Amiodarone:** Unlike Sotalol, chronic administration of Amiodarone is well-known to **increase** the DFT. This is a critical clinical consideration for patients with ICDs, as it may necessitate increasing the device's energy output settings. * **Verapamil and Diltiazem:** These are Class IV antiarrhythmics (Calcium Channel Blockers). While they affect the AV node and heart rate, they have **no significant effect** on the defibrillation threshold. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs that Decrease DFT (Make defibrillation easier):** Sotalol, Dofetilide, and Bretylium. * **Drugs that Increase DFT (Make defibrillation harder):** Amiodarone, Lidocaine, Mexiletine, and Phenytoin. * **Sotalol Side Effect:** Being a Class III agent, the most feared complication of Sotalol is **Torsades de Pointes** due to QT interval prolongation. * **Amiodarone vs. Sotalol:** Remember that while both are Class III, they have opposite effects on DFT. Amiodarone increases it; Sotalol decreases it.

Q: Which of the following drugs has the longest half-life?

Amiodarone. **Explanation:** The correct answer is **Amiodarone**. **1. Why Amiodarone is correct:** Amiodarone is a Class III antiarrhythmic drug known for its exceptional lipophilicity and extensive tissue distribution. It accumulates significantly in the adipose tissue, liver, and lungs. Due to this massive volume of distribution ($V_d$), it has an extraordinarily long elimination half-life, typically ranging from **25 to 60 days** (averaging several weeks). This necessitates the use of a loading dose to achieve steady-state plasma concentrations quickly. **2. Why the other options are incorrect:** * **Quinidine (Option B):** A Class IA antiarrhythmic with a half-life of approximately **6 to 8 hours**. * **Diltiazem (Option C):** A Class IV antiarrhythmic (Calcium Channel Blocker) with a relatively short half-life of **3 to 4.5 hours**, often requiring sustained-release formulations for long-term management. * **Procainamide (Option D):** A Class IA antiarrhythmic with a very short half-life of **3 to 4 hours**. Its active metabolite, N-acetylprocainamide (NAPA), has a longer half-life (6–10 hours) but is still significantly shorter than Amiodarone. **3. High-Yield Clinical Pearls for NEET-PG:** * **Iodine Content:** Amiodarone contains about 37% iodine by weight, leading to thyroid dysfunction (Hypothyroidism/Wolff-Chaikoff effect or Hyperthyroidism/Jod-Basedow phenomenon). * **Adverse Effects:** Due to its long half-life, toxicities take a long time to resolve. Key side effects include **pulmonary fibrosis** (most serious), corneal micro-deposits, bluish-grey skin discoloration, and hepatotoxicity. * **Monitoring:** Patients on long-term Amiodarone require regular Pulmonary Function Tests (PFTs), Liver Function Tests (LFTs), and Thyroid Function Tests (TFTs).

Q: A 23-year-old pregnant woman presents with features of dilated cardiomyopathy. Which of the following drugs should NOT be given for her treatment?

ACE inhibitors. **Explanation:** The management of heart failure or dilated cardiomyopathy in pregnancy requires careful consideration of fetal safety. **1. Why ACE Inhibitors are Contraindicated:** ACE inhibitors (e.g., Enalapril, Lisinopril) and Angiotensin Receptor Blockers (ARBs) are strictly **contraindicated (Category X/D)** during pregnancy, especially in the second and third trimesters. They interfere with the fetal renin-angiotensin system, leading to **fetal renal dysgenesis**, oligohydramnios, pulmonary hypoplasia, intrauterine growth restriction (IUGR), and cranial ossification defects. If a patient is on these drugs and becomes pregnant, they must be switched to safer alternatives immediately. **2. Analysis of Other Options:** * **Digoxin:** It is considered safe during pregnancy (Category C) and is often used to control heart rate or improve contractility in maternal heart failure. * **Diuretics (e.g., Furosemide):** While used cautiously to avoid placental hypoperfusion due to volume depletion, they are not absolute contraindications and are frequently used to manage acute pulmonary edema in pregnant patients. * **Hydralazine and Nitrates:** These are the preferred vasodilators for afterload reduction in pregnant women with heart failure instead of ACE inhibitors. **Clinical Pearls for NEET-PG:** * **Teratogenic effect of ACEIs:** "Fetal Renal Tubular Dysgenesis" is a high-yield keyword. * **Safe Antihypertensives in Pregnancy:** Remember the mnemonic **"Better Mother Love Her Child"** — **B**eta-blockers (Labetalol), **M**ethyldopa (Drug of choice for chronic HTN), **L**abetalol, **H**ydralazine, **C**alcium Channel Blockers (Nifedipine). * **Peripartum Cardiomyopathy:** Usually occurs in the last month of pregnancy or within 5 months postpartum; Bromocriptine is sometimes used in its management.

Q: Which beta-blocker increases HDL-cholesterol?

Celiprolol. ### Explanation **Correct Option: A. Celiprolol** Beta-blockers typically have an adverse effect on lipid profiles, often increasing triglycerides and decreasing HDL-cholesterol (the "good" cholesterol) [2]. However, **Celiprolol** is a unique, third-generation cardioselective beta-1 antagonist with **partial beta-2 agonist activity** [1]. This intrinsic sympathomimetic activity (ISA) at beta-2 receptors promotes peripheral vasodilation and stimulates lipoprotein lipase, which leads to an **increase in HDL-cholesterol** and a reduction in triglycerides [3]. This makes it metabolically "friendly" compared to traditional beta-blockers. **Analysis of Incorrect Options:** * **B. Nebivolol:** While it is a highly selective beta-1 blocker with nitric oxide (NO)-mediated vasodilatory properties, it is generally considered **lipid-neutral** [1]. It does not significantly increase HDL. * **C. Carvedilol:** This is a non-selective beta and alpha-1 blocker. While it is metabolically superior to older drugs like Propranolol (it does not worsen insulin resistance or significantly lower HDL), it does not actively increase HDL levels like Celiprolol [1]. * **D. Metoprolol:** A standard second-generation cardioselective beta-1 blocker. It is notorious for traditional beta-blocker side effects, including a **decrease in HDL** and an increase in plasma triglycerides. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolic Neutrality:** Third-generation beta-blockers (Celiprolol, Carvedilol, Nebivolol) are preferred in patients with Diabetes or Dyslipidemia [1]. * **ISA Property:** Drugs with Intrinsic Sympathomimetic Activity (e.g., Pindolol, Celiprolol) cause less bradycardia and fewer lipid disturbances [3]. * **Celiprolol's Unique Profile:** It is also a weak alpha-2 antagonist, further contributing to its vasodilatory effect [3]. It is often the drug of choice in patients with **Vascular Ehlers-Danlos Syndrome**.

Q: Which of the following drugs is least useful in the management of congestive cardiac failure?

Trimetazidine. **Explanation:** The management of Congestive Cardiac Failure (CCF) focuses on improving hemodynamics, reducing remodeling, and enhancing myocardial contractility [2]. **Why Trimetazidine is the correct answer:** Trimetazidine is a **metabolic modulator** (pFOX inhibitor) that shifts myocardial metabolism from fatty acid oxidation to glucose oxidation. While it is highly effective in managing **chronic stable angina** by optimizing oxygen utilization, it has no direct effect on cardiac contractility, preload, or afterload. Large-scale clinical trials have not established it as a standard therapy for the management of heart failure, making it the "least useful" among the given options. **Analysis of other options:** * **Bucindolol:** A non-selective **beta-blocker** with mild alpha-blocking properties. Beta-blockers (like Carvedilol, Metoprolol, and Bisoprolol) are a cornerstone of CCF management as they reduce remodeling and mortality [1], [2]. * **Pimobendan:** A **calcium sensitizer** and PDE3 inhibitor. It acts as an "inodilator," increasing cardiac contractility and causing vasodilation, used specifically in acute or refractory heart failure [1], [2]. * **Vesnarinone:** An **ionotropic agent** with multiple mechanisms (PDE3 inhibition and sodium channel modulation) [2]. Though its long-term use is limited by side effects, it is pharmacologically classified as a drug for heart failure. **High-Yield Clinical Pearls for NEET-PG:** * **Beta-blockers in CCF:** Only specific ones (Bisoprolol, Carvedilol, Metoprolol succinate, and Nebivolol) are proven to reduce mortality [1]. * **Inodilators:** Drugs like Milrinone and Pimobendan are used in decompensated CCF but may increase the risk of arrhythmias [2]. * **Trimetazidine Side Effect:** It can cause **Parkinsonian symptoms** (tremors, rigidity) in elderly patients, a frequent "catch" in pharmacology questions.

Q: Which angiotensin receptor blocker also has PPAR gamma activity?

Telmisartan. **Explanation:** **Telmisartan** is unique among Angiotensin II Receptor Blockers (ARBs) because it acts as a **selective partial agonist of Peroxisome Proliferator-Activated Receptor gamma (PPAR-γ)**. 1. **Why Telmisartan is correct:** Structurally, telmisartan resembles ligands that bind to PPAR-γ (a nuclear receptor primarily involved in glucose and lipid metabolism). By activating PPAR-γ, telmisartan improves insulin sensitivity, reduces glucose levels, and exerts anti-inflammatory effects. This makes it particularly beneficial for hypertensive patients with **metabolic syndrome or Type 2 Diabetes Mellitus**. 2. **Why other options are incorrect:** * **Losartan:** Known for its unique **uricosuric property** (inhibits URAT1 transporter), making it the drug of choice for hypertensive patients with Gout. It does not have significant PPAR-γ activity. * **Candesartan & Valsartan:** These are potent, selective AT1 receptor blockers but lack the structural configuration required to modulate the PPAR-γ receptor. They are primarily used for hypertension and heart failure (especially Valsartan in post-MI patients). **High-Yield Clinical Pearls for NEET-PG:** * **Longest Half-life:** Telmisartan has the longest half-life (~24 hours) among all ARBs, allowing for once-daily dosing. * **Dual Benefit:** It is often referred to as a "Metabosartan" due to its dual action on blood pressure and metabolic parameters. * **Teratogenicity:** Like ACE inhibitors, all ARBs are **contraindicated in pregnancy** (Category D) as they cause fetal renal anomalies and oligohydramnios. * **Side Effect:** Unlike ACE inhibitors, ARBs do not cause a dry cough because they do not interfere with Bradykinin metabolism.

Question 1

Supraventricular tachycardia can be managed best by:

Accepted Answer

Adenosine

Answer

Digitalis

Answer

Disopyramide

Answer

Quinidine

Question 2

Which of the following drugs has been used in the treatment of angina by the inhalation route with a very rapid onset and short duration of action?

Accepted Answer

Amyl nitrite

Answer

Isosorbide dinitrate

Answer

Isosorbide mononitrate

Answer

Nitroglycerin

Question 3

Which antihistamine is associated with an increased risk of cardiac arrhythmias when co-administered with erythromycin or ketoconazole?

Accepted Answer

Terfenadine

Answer

Diphenhydramine

Answer

Clemastine

Answer

Loratadine

Question 4

Which of the following decreases defibrillation threshold?

Accepted Answer

Sotalol

Answer

Amiodarone

Answer

Verapamil

Answer

Diltiazim

Question 5

Which of the following drugs has the longest half-life?

Accepted Answer

Amiodarone

Answer

Quinidine

Answer

Diltiazem

Answer

Procainamide

Question 6

A 23-year-old pregnant woman presents with features of dilated cardiomyopathy. Which of the following drugs should NOT be given for her treatment?

Accepted Answer

ACE inhibitors

Answer

Digoxin

Answer

Diuretics

Answer

Diuretics

Question 7

A patient presents to the casualty department in an unconscious state with a blood pressure of 220/110 mm Hg. What is the most suitable drug for this patient to rapidly decrease the blood pressure?

Accepted Answer

Intravenous infusion of sodium nitroprusside

Answer

Sublingual nifedipine

Answer

Intramuscular injection of hydralazine

Answer

Intravenous injection of clonidine

Question 8

Which beta-blocker increases HDL-cholesterol?

Accepted Answer

Celiprolol

Answer

Nebivolol

Answer

Carvedilol

Answer

Metoprolol

Question 9

Which of the following drugs is least useful in the management of congestive cardiac failure?

Accepted Answer

Trimetazidine

Answer

Bucindolol

Answer

Pimobendan

Answer

Vesnarinone

Question 10

Which angiotensin receptor blocker also has PPAR gamma activity?

Accepted Answer

Telmisartan

Answer

Candesartan

Answer

Valsartan

Answer

Losartan

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?